ArticleBritish journal of cancer1993
Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer.
Article in British journal of cancer, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 119 citations in OpenAlex.
- Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells.British journal of cancer · 1999Trial
- Integrative analysis of tumor-educated platelets for stage-specific diagnosis, prognosis, and therapy in ovarian cancer.Discover oncology · 2026Article
- Identification of VWA5A as a novel biomarker for inhibiting metastasis in breast cancer by machine-learning based protein prioritization.Scientific reports · 2024Article
- Article
- Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients.Molecular oncology · 2015Article
- CancerMA: a web-based tool for automatic meta-analysis of public cancer microarray data.Database : the journal of biological databases and curation · 2012Article
- Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder.British journal of cancer · 2001Article
- Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas.The American journal of pathology · 2001Article
- Localization of multiple melanoma tumor-suppressor genes on chromosome 11 by use of homozygosity mapping-of-deletions analysis.American journal of human genetics · 2000Article
- Somatic mutations of the PPP2R1B candidate tumor suppressor gene at chromosome 11q23 are infrequent in ovarian carcinomas.Neoplasia (New York, N.Y.) · 1999Article
- Functional localization of a melanoma tumor suppressor gene to a small (< or = 2 Mb) region on 11q23.Oncogene · 1999Article
- Article
- 11q23.1 and 11q25-qter YACs suppress tumour growth in vivo.Oncogene · 1999Article
- Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
- Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
- The long and short of chromosome 11 in breast cancer.The American journal of pathology · 1998Article
- Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinomas of the uterine cervix.British journal of cancer · 1998Article
- Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines.British journal of cancer · 1997Article
- Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes.British journal of cancer · 1997Article
- Fine mapping of an imprinted gene for familial nonchromaffin paragangliomas, on chromosome 11q23.American journal of human genetics · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 11q13 chromosomal region encodes oncogenes relevant to a variety of human cancers as well as a tumour suppressor gene implicated in multiple endocrine neoplasia type 1. In addition, high affinity folate receptor (FOLR1), which maps to 11q13.3-13.5, is expressed at an elevated level on the surface of over 80% of nonmucinous epithelial ovarian cancers. Further telomeric, 11q breakpoints are found in many cancers. We studied the involvement of 11q markers in ovarian cancer by looking for tumour-specific loss of heterozygosity (LOH), as well as amplification or rearrangements that might explain the overexpression of FOLR1. Twenty eight epithelial ovarian cancers, along with lymphocyte DNA from the same individual were used for Southern blotting with polymorphic probes from 11q. PCR primers from 11q23.3 were also used. The 11q13 band was amplified in four out of 28 cancers. The amplicon included the probe D11S146 as well as FGF3 (formerly INT2) and FOLR1 in one out of these four cases, thus crossing the bcl1 translocation breakpoint. LOH was seen in three out of 16 cases with FGF3 (11q13). A much higher frequency of LOH (8/12) was found at 11q23.3-qter, implying the presence of a tumour suppressor gene in this region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.